Belgium-AstraZeneca/Side Effects

Blood clots linked to AstraZeneca COVID-19 vaccine, listed as very rare side effects: EMA

  • English
  • Français
  • العربية
  • Pусский
  • Español
  • 日本語
  • Deutsch

Shotlist


Beijing, China - April 8, 2021 (CCTV - No access Chinese mainland)
1. Screenshot of agenda of European Medicines Agency (EMA) press briefing on the conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of COVID-19 Vaccine AstraZeneca and thromboembolic events

FILE: Brussels, Belgium - 2019 (CGTN - No access Chinese mainland)
2. Headquarter of European Commission, EU flags
3. People entering headquarter of European Commission

FILE: Bristol, UK - 2021 (CGTN - No access Chinese mainland)
4. Various of medical worker preparing for vaccination with AstraZeneca vaccine
5. Various of elderly woman being inoculated with AstraZeneca vaccine

FILE: Shanghai, China - Date Unknown (CCTV - No access Chinese mainland)
6. Sign reading (Chinese/English) "AstraZeneca"
7. Information board showing slogans of AstraZeneca

FILE: Malmo, Sweden - Nov 23, 2015 (CCTV - No access Chinese mainland)
8. Swedish national flag

FILE: Stockholm, Sweden - Dec 11, 2018 (CGTN - No access Chinese mainland)
9. Cruise ship
10. Riverside buildings

FILE: Reykjavik, Iceland - Oct 2, 2019 (CCTV - No access Chinese mainland)
11. Prime Minister's Office Building
12. Various of traffic on street

Storyline


The European Medicines Agency (EMA) confirmed on Wednesday that the occurrence of blood clots with low blood platelets are strongly associated with the administration of AstraZeneca COVID-19 vaccine, but should be still listed as very rare side effects.

In its latest assessment, EMA experts told the media that the reported combination of blood clots and low blood platelets is very rare, and the overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.

The drug regulator said in a statement that there were no specific risk factors, including age, although most of the cases reported have occurred in women under 60 years of age within two weeks of vaccination.

The findings were released after the watchdog assessed the over 80 cases of people who developed clots in blood veins and in arteries after receiving the jabs. Eighteen of these cases have proved fatal.

The agency thus reminded healthcare professionals and people receiving the vaccine to remain aware of the possibility of the occurrence of the side effects within two weeks of vaccination.

EMA chief Emer Cooke told a news conference that COVID-19 is a very serious disease with high hospitalization and death rates and everyday COVID is still causing thousands of deaths across the EU. This vaccine has proven to be highly effective - it prevents severe disease and hospitalization, and it is saving lives.

EMA's safety committee chair, Sabine Straus, said the investigation was unable to determine the cause of the blood clotting and that further investigations, which involve manufacturer AstraZeneca, have been commissioned.

The scientific review came after several European countries halted or suspended the vaccine's roll-out in view of reported risks.

DOWNLOAD
  • ID : 8186489
  • Dateline : April 8, 2021/File
  • Location : Belgium;China
  • Category : health
  • Duration : 1'06
  • Audio Language : Nats
  • Source : China Central Television (CCTV),China Global Television Network (CGTN)
  • Restrictions : No access Chinese mainland
  • Published : 2021-04-08 04:36
  • Last Modified : 2021-04-08 16:30:00
  • Version : 1
  • ID : 8186489
  • Dateline : 8 avr. 2021/Archives
  • Location : Belgique;Chine
  • Category : health
  • Duration : 1'06
  • Audio Language : Nats
  • Source : China Central Television (CCTV)
  • Restrictions : Pas d’accès dans la partie continentale de Chine
  • Published : 2021-04-08 16:00
  • Last Modified : 2021-04-08 16:30:00
  • Version : 1
  • ID : 8186489
  • Dateline : 8 أبريل 2021/أرشيف
  • Location : بلجيكا;الصين
  • Category : health
  • Duration : 1'06
  • Audio Language : الصوت الطبيعي
  • Source : China Central Television (CCTV),China Global Television Network (CGTN)
  • Restrictions : No access Chinese mainland
  • Published : 2021-04-08 16:09
  • Last Modified : 2021-04-08 16:30:00
  • Version : 1
  • ID : 8186489
  • Dateline : 8 апр 2021/Архив
  • Location : Бельгия;Китай
  • Category : health
  • Duration : 1'06
  • Audio Language : Естественный звук
  • Source : China Central Television (CCTV)
  • Restrictions : Недоступно материковой части Китая
  • Published : 2021-04-08 15:47
  • Last Modified : 2021-04-08 16:30:00
  • Version : 1
  • ID : 8186489
  • Dateline : 8 abr. 2021/Archivo
  • Location : Bélgica;China
  • Category : health
  • Duration : 1'06
  • Audio Language : Nats
  • Source : China Central Television (CCTV)
  • Restrictions : No acceso a la parte continental de China
  • Published : 2021-04-08 16:24
  • Last Modified : 2021-04-08 16:30:00
  • Version : 1
  • ID : 8186489
  • Dateline : 2021年4月8日/資料
  • Category : health
  • Duration : 1'06
  • Audio Language : 自然音声
  • Source : China Central Television (CCTV),China Global Television Network (CGTN)
  • Restrictions : 中国大陸での使用は不可
  • Published : 2021-04-08 14:34
  • Last Modified : 2021-04-08 16:30:00
  • Version : 1
  • ID : 8186489
  • Dateline : 8. April 2021/ Archiv
  • Category : health
  • Duration : 1'06
  • Audio Language : Originalton
  • Source : China Central Television (CCTV),China Global Television Network (CGTN)
  • Restrictions : Für das chinesische Festland nicht verfügbar
  • Published : 2021-04-08 15:23
  • Last Modified : 2021-04-08 16:30:00
  • Version : 1

Belgium-AstraZeneca/Side Effects

Blood clots linked to AstraZeneca COVID-19 vaccine, listed as very rare side effects: EMA

Dateline : April 8, 2021/File

Location : Belgium;China

Duration : 1'06

  • English
  • Français
  • العربية
  • Pусский
  • Español
  • 日本語
  • Deutsch


Beijing, China - April 8, 2021 (CCTV - No access Chinese mainland)
1. Screenshot of agenda of European Medicines Agency (EMA) press briefing on the conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of COVID-19 Vaccine AstraZeneca and thromboembolic events

FILE: Brussels, Belgium - 2019 (CGTN - No access Chinese mainland)
2. Headquarter of European Commission, EU flags
3. People entering headquarter of European Commission

FILE: Bristol, UK - 2021 (CGTN - No access Chinese mainland)
4. Various of medical worker preparing for vaccination with AstraZeneca vaccine
5. Various of elderly woman being inoculated with AstraZeneca vaccine

FILE: Shanghai, China - Date Unknown (CCTV - No access Chinese mainland)
6. Sign reading (Chinese/English) "AstraZeneca"
7. Information board showing slogans of AstraZeneca

FILE: Malmo, Sweden - Nov 23, 2015 (CCTV - No access Chinese mainland)
8. Swedish national flag

FILE: Stockholm, Sweden - Dec 11, 2018 (CGTN - No access Chinese mainland)
9. Cruise ship
10. Riverside buildings

FILE: Reykjavik, Iceland - Oct 2, 2019 (CCTV - No access Chinese mainland)
11. Prime Minister's Office Building
12. Various of traffic on street


The European Medicines Agency (EMA) confirmed on Wednesday that the occurrence of blood clots with low blood platelets are strongly associated with the administration of AstraZeneca COVID-19 vaccine, but should be still listed as very rare side effects.

In its latest assessment, EMA experts told the media that the reported combination of blood clots and low blood platelets is very rare, and the overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.

The drug regulator said in a statement that there were no specific risk factors, including age, although most of the cases reported have occurred in women under 60 years of age within two weeks of vaccination.

The findings were released after the watchdog assessed the over 80 cases of people who developed clots in blood veins and in arteries after receiving the jabs. Eighteen of these cases have proved fatal.

The agency thus reminded healthcare professionals and people receiving the vaccine to remain aware of the possibility of the occurrence of the side effects within two weeks of vaccination.

EMA chief Emer Cooke told a news conference that COVID-19 is a very serious disease with high hospitalization and death rates and everyday COVID is still causing thousands of deaths across the EU. This vaccine has proven to be highly effective - it prevents severe disease and hospitalization, and it is saving lives.

EMA's safety committee chair, Sabine Straus, said the investigation was unable to determine the cause of the blood clotting and that further investigations, which involve manufacturer AstraZeneca, have been commissioned.

The scientific review came after several European countries halted or suspended the vaccine's roll-out in view of reported risks.

ID : 8186489

Published : 2021-04-08 04:36

Last Modified : 2021-04-08 16:30:00

Source : China Central Television (CCTV),China Global Television Network (CGTN)

Restrictions : No access Chinese mainland

More



Login
Username
Password
code
Sign In
OK